40M, trading at HK$0.30 on the HKSE. This SniperIQ fundamentals page covers Wai Yuen Tong Medicine Holdings's valuation (P/E 84.7x, P/B 0.3x), profitability (net margin 0.6%), revenue (HK$683M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
40M
P/E (TTM)84.7x
Net Margin0.6%
Revenue (FY25)HK$683M

Full research coverage

Frequently Asked Questions

What is Wai Yuen Tong Medicine Holdings's market cap?

Wai Yuen Tong Medicine Holdings (0897) has a market capitalization of approximately HK

40M, trading at HK$0.30 on the HKSE. Market cap moves with the live share price.

What is Wai Yuen Tong Medicine Holdings's P/E ratio?

Wai Yuen Tong Medicine Holdings's trailing twelve-month P/E ratio is 84.7x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Wai Yuen Tong Medicine Holdings?

Wai Yuen Tong Medicine Holdings runs a net profit margin of 0.6%, a gross margin of 53.0%, and an operating margin of -2.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Wai Yuen Tong Medicine Holdings generate?

Wai Yuen Tong Medicine Holdings reported revenue of HK$683M for fiscal year 2025, with net income of HK$4M and earnings per share (EPS) of 0.0036. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Wai Yuen Tong Medicine Holdings pay a dividend?

Wai Yuen Tong Medicine Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Wai Yuen Tong Medicine Holdings financially healthy?

Wai Yuen Tong Medicine Holdings carries a debt-to-equity ratio of 0.24x and a current ratio of 1.40x, with a market beta of -0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Wai Yuen Tong Medicine Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wai Yuen Tong Medicine Holdings (0897) the key facts are: market cap HK

40M, P/E 84.7x, revenue HK$683M, 52-week range 0.27-0.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Wai Yuen Tong Medicine Holdings's full fundamentals live

Get Wai Yuen Tong Medicine Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.